Genetic variability within the cholesterol lowering pathway and the effectiveness of statins in reducing the risk of MI.

ABSTRACT: Genetic variability has been shown to affect statin responsiveness. Participants from the Utrecht Cardiovascular Pharmacogenetics (UCP) studies were enrolled from a population-based registry of pharmacy records linked to hospital discharge records (PHARMO) to investigate tagging SNPs within candidate genes involved in the cholesterol lowering pathway for modification of the effectiveness of statins in reducing the risk of myocardial infarction (MI). Patients who received a prescription for an antihypertensive drug and/or had hypercholesterolemia were selected from the PHARMO database. We designed a nested case-control study in which cases were hospitalized for MI and controls were not. Patients were contacted through their community pharmacies. For this study, only hypercholesterolemic par

SUBMITTER: Peters BJ 

PROVIDER: S-EPMC3465613 | biostudies-literature | 2011 Aug

REPOSITORIES: biostudies-literature